Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Enhance patient care by using the only objective, quantitative arterial analysis software validated through histology and based on CTA technology. This innovative tool employs ground-truth histological data to reveal the origins of myocardial ischemia, helping to assess risks for heart attacks and strokes. These critical events are often driven by unstable, non-obstructive plaques within the arteries that remain undetected and unaddressed. Traditional non-invasive diagnostic methods fall short, as they cannot penetrate deep into the arterial walls where heart disease begins to manifest. Elucid is leveraging advanced scientific imaging alongside artificial intelligence to facilitate rapid, reliable, and non-invasive diagnoses, ultimately leading to tailored treatment strategies for cardiovascular conditions and improved patient outcomes. With this histology-validated software, you can evaluate plaque composition and determine the risks of heart attacks and strokes with unmatched precision. This comprehensive, objective visualization of arterial health empowers healthcare providers to devise customized treatment approaches well before a patient arrives for hospital care, significantly enhancing the quality of healthcare delivery.
Description
Specialty and rare diseases often encompass patient populations that are not clearly defined, including individuals who remain undiagnosed or face misdiagnoses, along with healthcare providers who may lack knowledge about these conditions and their various manifestations, resulting in treatment pathways that are poorly understood. IPM.ai operates as an Insights-as-a-Service (IaaS) firm, dedicated to empowering leading life sciences organizations to gain deeper insights into patient care and enhance the quality of life for those affected through the development, clinical research, and commercialization of therapeutic solutions. By predicting market size, analyzing the competitive landscape, and estimating potential return on investment, companies can optimize their commercialization strategies. Additionally, the platform identifies undiagnosed and misdiagnosed individuals who could benefit from early disease interception and therapeutic measures. It employs statistical models to gauge the prevalence of specific diseases within certain patient populations at any given moment. Furthermore, IPM.ai helps pinpoint physicians who are adept at diagnosing and treating these ideal patients, while also influencing other healthcare providers to enhance overall patient outcomes. This comprehensive approach ultimately aims to bridge the gap in understanding and addressing the needs of those with rare diseases.
API Access
Has API
API Access
Has API
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
Elucid
Country
United States
Website
elucid.com
Vendor Details
Company Name
IPM.ai
Country
United States
Website
www.ipm.ai/platform